Invida is a privately-held healthcare company formed in 2005 with headquarters in Singapore and over 4000 employees across 13 countries. The document provides an overview of Invidia's vision, capabilities, partnerships, and geographic footprint, with a focus on their operations and capabilities in India. In India, Invidia has over 800 sales and marketing professionals covering 19 clients, including major brands like Pyridium, GSK Consumer Health, and Eli Lilly. The summary highlights Invidia's sales force management, regulatory expertise, and commercialization solutions in India.

1. Invida Profile AUGUST 2010

3. India capabilities.

4. CORPORATE OVERVIEW

6. Quintiles, Temasek & Zuellig Group

7. Headquarters: Singapore

8. Employees: 4000+ professionals across 13 countries (ex-Japan)

9. $50B market*

10. Double-digit growth

11. 2009 est. Revenue

12. Approx. $200M; 5-yr. CAGR: 25%

13. Profitable with positive cash flow*source: WHO, McKinsey & Co.

14. Invida’s Vision To be the leading provider of important healthcare brands and services to improve the lives of people in the Asia Pacific region.

15. Partnering is a Core Strategy

16. Fundamental Business Model Commercialization Regulatory Development Research Manufacturing Proprietary Products Commercialization Solutions Partnered Products

18. E.D.G.E marketing process

19. 4000+ sales force covering PC, Specialty and OTC

20. Supply Chain and logistics management

21. Phase IV Capability with on-going trials

22. Established Medical Advisory and KOL network across TAs

23. Pre-launch Medical Liaison

24. Industry Standard SOPs implemented in PV and Marketing practices

25. Centrally coordinated from Singapore

26. 32 experts interacting locally with authorities

27. 40 NCEs filed since 2006

28. 60 cosmetics & 18 device applications

30. EDGE ensures consistency and optimal brand performance across highly fragmented and dynamic markets for Invida and our partnersBrand manager, medical, sales Brand manager, medical, sales Brand manager, medical, sales Brainstorm with large group Mid-sized group Marketers Brand strategy evaluation Monitoring KPI’s action Plan Budget Scenario’s & Sales Force Requirements Brand Opportunities Market evaluation Key Actions Strategic Drivers Customer segmentation Monitoring Synthesis Creation Analysis Evaluation

32. Satisfactory audit outcomes from many partners

33. Invida is an ISO 2000 approved company.

34. Regional Operational Excellence function ensures all new teams undergo standardized training.

35. Also governs Sales Force Effectiveness Programs and monitors Key Performance Indicators.

36. National sales teams can be recruited within a 6-8 week period.

37. “Recruit, Train, On-boarding” cycle optimized for rapid deliveryMarketing Optimization Risk Management Speed to Market Supports Supports Supports Supports Supports Supports Sales, Marketing and Operational Excellence

38. Operational Excellence Management Motivation ETMS/CRMS

39. Asia Pacific Footprint SINGAPORE Executive Team Regional Regulatory, Medical and Marketing Singapore Sales: 10 SOUTH KOREA Sales: 45 CHINA Sales: 350 HONG KONG Sales: 21 INDIA Sales: 807 PHILIPPINES Sales: 1,000 TAIWAN Sales: 26 MALAYSIA Sales: 128 VIETNAM Sales: 115 INDONESIA Sales: 206 THAILAND Sales: 299 AUSTRALIA & NZ Sales: 230 Invida Infrastructure Investments

41. Financial Terms: Upfront, staggered payments +/or royalties, product supply

42. Divest non-core assets or portfolio

43. Realize financial potential through royalties & supply

44. Quickest route to product value realization

45. Full rights to products acquired by Invida

46. Branded as in Invida product

47. Pharma MNC – Mature brands

48. Specialty Pharma

50. Financial Terms: Margin Sharing for Agency;

51. In-licensing can include upfront, milestones and royalties

52. Achieve regional sales with minimal investment

53. Risk sharing but exposure to product upside potential

54. Single brand or portfolio

55. Agency model retains partners branding

56. Agency : Marketing and distribution rights over defined time period, sold under originators name

57. In-licensing: Perpetual as long as IP is intact (CRE), sold under Invida

58. Pharma MNC – Mature brands

59. Specialty Pharma

61. Fees: merit/commission based typically fully loaded costs plus margin on sales or success fee

62. Or cost plus service fee

63. Fully outsourced S&M headcount

64. Full control

65. Partner books sales

66. CSO or CSMO

67. Partner retains control and outsources the S&M activity by brand

68. Dedicated or syndicated sales forces

69. Pharma MNC – All Products

71. INVIDA INDIA

72. India Specific Capabilities Key Facts Country Revenue Contribution Total head count: 868 (801 in sales & marketing team) Key strengths in Nutrition, Diabetic, Pain management and Anti-Infective Major Own Brands Major Partners Brand TC Partner TC Pyridium UTI GSK CH Nutrition Dental Care Distaclor Anti-infectives J&J Medical Devices Eli Lilly Insulin Launching Dermatology Division in August’10

73. IndiaClients 19

74. Revenue contribution Revenue Contribution by Deal Type

75. August 29, 2010 Confidential 21 Ability to Execute Minimum Disruption Why Flexibility ? Proven Capability Value Invida India capability Quality 21 29 August 2010

76. August 29, 2010 Confidential 22 40 8 31 57 84 16 25 31 70 20 38 17 10 117 60 72 86 43 Invida India Today 22 29 August 2010

77. Invida India – Organogram MD EA BD Dir. Fin Dir. Marketing Mgr. Per. Dir. Com Dir. Sales Acct Mktg. Sales Personnel IT Statutory Admin Regulatory HR Training Dist Audit OE Finance ISO

78. 24 Indian Management Team Singapore Management Team John Graham CEO Girdhar Balwani General Manager India Anne Bell CFO Christopher Tay CAO Girisan Kariangal Director- Marketing Sharad Virmani Director-Sales Renaat Jansen VP Alliance Ops & Primary Care Brian Forrester VP Consumer Health Bhaven Shah Director-Commercial SumeetSud Chief Marketing Officer George Eassey EVP Commercial Operations Team Invida

79. August 29, 2010 Confidential 25 DoctorExposure 146 K doctors on list

80. August 29, 2010 Confidential 26 MarketCoverage 688 259 20 7031 174 3966 104 7701 7611 3249 5576 2431 12689 5370 327 57 4046 349 148 190 3976 7765 12526 3644 5154 341 152 217 10188 7495 6736 5909 194 12333 273 5627 10788 12299 4213 Network of 25 CA’s 7700 95 9666 311 5260 1,46,000 Doctor 209 Chemist 85,198 16366 8676 9361 Stockists 3493 359 4703 169 26 29 August 2010

81. August 29, 2010 Confidential 27 TC coverage 27 29 August 2010

83. Speedy recruitment across the country

84. Team high on discipline, values and ethics

85. RCPA to regularly validate customer list (Drs/Hospitals)

86. Availability of doctor lists across India, validated thru periodic targeting and segmentation exercise

87. A comprehensive e-reporting on frequent intervals at all levels of the sales hierarchy

89. Brand Bonding Ladder

90. SOPs for MDAs especially CMEs ensuring better ROI for the activity

91. Continuous training through class room and Distant Learning Program

92. Regulatory experience of last 5 years

95. Number Crunching

96. Data Interpreting

97. Data Analyzing

98. Data Translating

99. FindingsCounter Check OE Executive Data Bank Dynamics Field OE Decision Analysis B U Heads Dir. Sales Client

100. Distribution software Inventory, collection controls from Head Office - Built in facility to restrict rights of particular users Software available as single user or multiple user Migration to higher version at very minimum additional cost Minimum technical errors with easy replicability Online support or by authorized agent of local city for resolving technical errors Facility to generate customized reports within minimal cost & time Fast data retrievability - from across the places / cities within fraction of time through internet

101. Resources Well defined Marketing Department EDGE – An unique brand planning process to create global brands Organized logistics Pan India coverage with 25 CAs, 840 stockists for own brands Matrix H.R Department Placement consultant in each state, Strong candidate data bank, Monthly modules on learning & motivation Regulatory Network Regulatory experience & network built up over 8 years 29 August 2010 33

103. Portfolio Expansion

104. Anti Infectives – 2

105. Iron Sucrose InjMajor Own Brands Customer Reach TC Brand Pyridium UTI Distaclor Anti-infectives

107. Regain the confidence of medical fraternity  Doctors + Chemist + Stockist

108. Optimize share of voice amongst Gyn / G.P / Uro

109. Institution break through in Govt/Semi Govt/Private hospitals

110. Retention of old prescribers + Incremental sales from young Doctors

113. Easy affordable brands for mass- Horlicks and Crocin range

114. Coverage of 24K multi specialists Pan India

116. Crocin-650: Established with aggressive POB drive, targets met (42% gr)

117. ActiBase: 453 USD’000s sales in first year (in 2008)

118. ActiGrow: 440 USD’000s sales in first year (in 2009)